The outperformance of the biotech sector in 2020 has been very narrow. The mega-cap names, such as Biogen, have done well, but the broader sector has been very average. #stocks #markets #economy #investing #financialservices #biotech $IBB $XBI https://t.co/mxjL7VUd1h